Echocardiography for transcatheter aortic valve implantation (original) (raw)

The Importance of Echocardiography in Transcatheter Aortic Valve Implantation

Echocardiography, 2014

Valvular heart diseases cause serious health problems in Turkey as well as in Western countries. According to a study conducted in Turkey, aortic stenosis (AS) is second after mitral valve disease among all valvular heart diseases. AS is frequently observed in elderly patients who have several cardiovascular risk factors and comorbidities. In symptomatic severe AS, surgical aortic valve replacement (AVR) is a definitive treatment. However, in elderly patients with left ventricular dysfunction and comorbidities, the risk of operative morbidity and mortality increases and outweighs the gain obtained from AVR surgery. As a result, almost one-third of the patients with serious AS are considered ineligible for surgery. Transcatheter aortic valve implantation (TAVI) is an effective treatment in patients with symptomatic severe AS who have high risk for conventional surgery. Since being performed for the first time in 2002, with a procedure success rate reported as 95% and a mortality rate of 5%, TAVI has become a promising method. Assessment of vascular anatomy, aortic annular diameter, and left ventricular function may be useful for the appropriate selection of patients and may reduce the risk of complications. Cardiac imaging methods including 2D and 3D echocardiography and multidetector computed tomography are critical during the evaluation of suitable patients for TAVI as well as during and after the procedure. In this review, we describe the role of echocardiography methods in clinical practice for TAVI procedure in its entirety, i.e. from patient selection to guidance during the procedure, and subsequent monitoring. (Echocardiography 2014;31:101-110)

The role of echocardiography in transcatheter aortic valve implantation

Interventional Cardiology, 2014

Aortic stenosis is a common valve disease with increasing prevalence in the elderly. The presence of comorbidities in this population can make surgical aortic valve replacement challenging; therefore, transcatheter aortic valve implantation is increasingly being offered as a management option for these patients. Imaging with echocardiography has an important role through all aspects of the procedure from initial imaging and patient selection, guidance of the procedure and assessment of complications.

TAVI imaging: over the echocardiography

La radiologia medica, 2020

Aortic valve stenosis (AS) is a common valvular heart disease. Recently, transcatheter aortic valve implantation (TAVI) has changed the treatment of severe AS in elderly patients with contraindications to traditional surgical replacement. Echocardiography is conventionally used as the first imaging modality to assess the presence and severity of AS and to provide anatomical and functional information. Nowadays, imaging techniques play a crucial role in the planning of TAVI to define suitable candidates. Computed tomography (CT) is essential to display the anatomy of the aortic valve complex (including aortic annulus, Valsalva sinuses, coronary arteries ostia, sinotubular junction), thoracoabdominal aorta, and vascular access. Cardiac CT may also provide the evaluation of coronary arteries in alternative to conventional coronary angiography. Magnetic resonance imaging may be alternative or supplementary in selected cases, providing detailed information of cardiac function and myocardial wall characteristics. More recently, advanced computer modeling image-based techniques can be used to support the evaluation of the feasibility and safety of TAVI procedures.

Computed tomography in the evaluation for transcatheter aortic valve implantation (TAVI)

Cardiovascular diagnosis and therapy, 2011

If left untreated, symptomatic, severe aortic stenosis (AS) is associated with a dismal prognosis. Open-heart surgical valve replacement is the treatment of choice and is associated with excellent short and long-term outcome. However, many older patients with multiple co-morbidities and anticipated increased surgical risk are excluded from surgical intervention. For these patients, transcatheter aortic valve implantation (TAVI) is emerging as a viable treatment alternative. Transcatheter valvular heart procedures are characterized by lack of exposure and visualization of the operative field, therefore relying on image guidance, both for patient selection and preparation and the implantation procedure itself. This article describes the role of multi-detector row computed tomography (MDCT) for detailed assessment of the aortic valve, aortic root, and iliac arteries in the context of TAVI.

Transthoracic echocardiography is adequate for intraprocedural guidance of transcatheter aortic valve implantation

Echo research and practice, 2017

While transcatheter aortic valve implantation (TAVI) has traditionally been supported intraprocedurally by transoesophageal echocardiography (TOE), transthoracic echocardiography (TTE) is increasingly being used. We evaluated echocardiographic imaging characteristics and clinical outcomes in patients who underwent TTE during TAVI (TTE-TAVI). A select team of dedicated sonographers and interventional echocardiographers performed TTE-TAVI in 278 patients, all of whom underwent TAVI through transfemoral access. We implanted the Medtronic EVOLUT R valve in 258 patients (92.8%). TTE images were acquired immediately pre-procedure by a dedicated sonographer in the cardiac catheterization laboratory with the patient in the supine position. TTE was then performed post deployment of TAVI. In the procedure, TTE image quality was fair or better in 249 (89.6%) cases. Color-flow Doppler was adequate or better in 275 (98.9%) cases. In 2 cases, paravalvular regurgitation (PVL) could not be assessed...

Experiences of Transcatheter Aortic Valve Implantation with Severe Aortic Stenosis

Haydarpasa Numune Training and Research Hospital Medical Journal, 2018

Introduction: Aortic stenosis is the most common and dangerous native valve disease and it affects 2-4% of the patients over 65 years of age. However, the surgical procedure leads the patients to undergo great risks, especially in the elderly population and in patients with concomitant disorders. In this retrospective study, we described and analyzed our experience on TAVI procedures performed in our hospital. Methods: After the approval of the Ethics Committee to conduct this study, patients' files from June 2012 to December 2014 were reviewed retrospectively and first 100 patients' demographic data, STS, EuroSCORE, aortic valve pressure gradients, the methods of anesthesia and monitoring and postoperative complications were collected. All of the data were expressed as mean±standard deviation. Results: Among 100 remaining patients, on whom data were collected, mean age was found as 78.6±6.7 years and 65 of the patients were female. The mean pulmonary artery pressure was 46.9±14.2 mmHg and mean pressure gradient (PG) was 48.8±10.7 mmHg, whereas the peak PG was 75.5±17.1 mmHg before the TAVI procedure; left ventricular ejection fraction before the TAVI procedure was calculated as 51.2±14.2%. Analysis of the patient charts revealed a mean value for STS as 7.8±4.7 and a mean value for EuroSCORE as 34.9±14.1%. In all patients, a probe for transesophageal echocardiography was inserted for real-time monitoring, together with a temporary pacemaker. Implanted valves were expandable CoreValve in 56%, and the Edwards Sapiens XT Valve in 43%. Following completion of the procedure, final femoral angiography was performed to verify that there were no vascular injuries. The patients were transferred coronary ICU after extubation. During postoperative period, minor complications were encountered in 11% of the patients. Discussion and Conclusion: The findings showed that TAVI was a procedure with a low rate of complications in patients with severe aortic stenosis when the steps of the procedure had been followed meticulously, according to the results of our retrospective study. The anesthesiologist should be a key member of the staff prior, during, and following the intervention. The ongoing prospective trials and retrospective research together with the debate on indications, type of the anesthesia, location where the procedure is held will shed light on the evolvement of this relatively novel technique.

Transcatheter Aortic Valve Implantation (TAVI) for the Treatment of Aortic Valve Stenosis: a Systematic Review

2015

Introduction: Aortic stenosis (AS) is the most common form of heart valve disease in the western world. As the population ages, this disease is becoming an increasing burden on patients and on the health care system. Current drug therapies (medical management (MM)) cannot reverse the course of AS. For most individuals with severe AS, surgical aortic valve replacement (SAVR), which requires open heart surgery and cardiopulmonary bypass, remains the standard therapy. However, a subgroup of patients with aortic stenosis are unsuitable for or at high risk to undergo SAVR due to their frailty or other comorbidities. Transcatheter aortic valve implantation (TAVI)-a novel, less invasive treatment option-was developed as an alternative for patients who are not suitable or at high risk for undergoing surgery. Objective: This study is intended to assess the feasibility, safety, efficacy and clinical effectiveness of TAVI, using the transfemoral (TF) and transapical (TA) approaches, in comparison to medical management or SAVR in patients with severe symptomatic AS; and to compare the outcomes associated with the two different approaches for valve implantation (TF and TA). Methods: A comprehensive literature search was conducted using eight electronic databases to identify studies of TAVI (TF and/or TA) for the treatment of AS. Data from the selected studies were extracted by two reviewers. Outcomes considered were feasibility, safety, efficacy and effectiveness of TAVI. Study quality was assessed and information was tabulated to identify trends or patterns. Results were pooled across studies for each outcome. iii Results: Fifty six relevant studies were identified: 37 studies (including seven comparative studies) assessed clinical outcomes, 14 studies discussed health-related quality of life, and five studies examined the impact of the learning curve on feasibility and safety of TAVI on patient outcomes. The overall procedural success rate was 96% (88%-100%). Studies that examined the learning curve for TAVI demonstrated it had a significant impact-increasing the procedural success rate and decreasing 30-day mortality. The mean combined periprocedural and cumulative all-cause mortality rate at 30 days for TAVI compared to the control groups (MM and/or SAVR) in the same or different studies was 9.0%, n = 10,500 vs 2.8%, n = 179, and 6.7%, n = 302, respectively. Permanent pacemaker implantation was three times more common with the Medtronic CoreValve compared to the Edwards SAPIEN prosthesis (26.5% vs 8.2%), but when both TAVI valves were compared with SAVR, there was no statistically significant difference. Major vascular complications occurred more frequently in the TF group (11.6%) than in the MM, SAVR or the TA groups. The rate of acute kidney injury requiring renal replacement therapy did not differ significantly between the TAVI and control groups, but was three times higher with the TA compared to the TF approach (7.3% vs 2.5%). TAVI achieved significant hemodynamic improvement as measured by echocardiography. The pooled estimate for moderate or severe paravalvular aortic regurgitation after TAVI was 7.2% (with no significant difference between TAVI approaches). Paravalvular aortic regurgitation occurred more frequently with TAVI than with SAVR. One year survival rates ranged from 68% to 77% for TAVI patients in the comparative studies and 72% to 85.3% in the case series studies. For MM and SAVR, the one year iv survival rate was 45% to 49.7% and 73.4% to 83%, respectively. Studies that compared patients' quality of life before and after TAVI found significant improvement at one-year follow-up. Conclusions: TAVI offers a safe and effective treatment for severe aortic stenosis in patients who are not suitable for or are at high risk to undergo SAVR. Unfortunately, current shortcomings in the evidence on long term outcomes make it difficult to determine the effectiveness of TAVI in high risk patients who may be candidates for surgery. v

Transcatheter aortic valve implantation: the new option for high-risk patients with aortic stenosis

Cardiology journal, 2011

Calcific aortic valve stenosis is the most common valvular heart disease in developed countries. Without surgery, the prognosis is extremely dismal. Therefore there is general agreement that surgical aortic valve replacement should be offered to patients with symptomatic severe aortic valve stenosis. However, surgery is denied to approx. 30-40% of elderly patients with severe, symptomatic aortic stenosis due to high perioperative risk. Transcatheter aortic valve implantation (TAVI) is a novel and effective procedure which provides a promising treatment option for some of these patients. This review focuses on TAVI systems, the patients who would benefit from TAVI, and the advantages and disadvantages of the procedure.